---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-209833"
form_type: "8-K"
ticker: "IRON"
cik: "0001816736"
company_name: "Disc Medicine, Inc."
filed_at: "2023-08-11T23:59:59+00:00"
generated_at: "2026-06-11T15:05:13.845023+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Disc Medicine Q2 net loss $15.9M, cash $378M; BEACON bitopertin data positive

## Summary
- Net loss $15.9M in Q2 2023 vs $9.6M in Q2 2022; R&D expense $12.1M, G&A $5.2M.
- Cash and equivalents $377.6M as of June 30, 2023; expected to fund operations into 2026.
- BEACON Phase 2 bitopertin data showed dose-dependent PPIX reduction, improved sunlight tolerance; well-tolerated.
- Enrolling two Phase 1b/2 studies for DISC-0974 (NDD-CKD and myelofibrosis); initial data expected year-end 2023.
- Completed upsized public offering in June 2023 for $157.8M gross proceeds.

## SEC filing metadata
- accession: 0001193125-23-209833
- form_type: 8-K
- ticker: IRON
- cik: 0001816736
- company_name: Disc Medicine, Inc.
- filed_at: 2023-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816736/000119312523209833/0001193125-23-209833-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816736/000119312523209833/d471506d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-209833
- JSON: https://secwatch.observer/filing/0001193125-23-209833.json
- Plain text: https://secwatch.observer/filing/0001193125-23-209833.txt

## Key facts
- Earnings Releases
  Disc Medicine, Inc. reported the quarter ended June 30, 2023 results: net income Net loss was $15.9 million for the quarter ended June 30, 2023.
  - Period: the quarter ended June 30, 2023
  - Net income: Net loss was $15.9 million for the quarter ended June 30, 2023
  - Result: reported results
  source text: Disc Medicine, Inc. (the "Company") announced its financial results for the quarter ended June 30, 2023 and provided a corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1816736/000119312523209833/0001193125-23-209833-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.